Idiopathic Parkinson's disease & idiopathic/primary restless legs syndrome. Monotherapy or in combination w/ l-dopa to control "on-off" fluctuations & reduce the total daily dose of l-dopa.
Parkinson's disease Initially 0.25 mg tds. Dose titration: Wk 1: 0.75 mg daily, wk 2: 1.5 mg daily, wk 3: 2.25 mg daily, wk 4: 3 mg daily. After the initial titration, wkly increments up to 3 mg daily may be given in 3 divided doses. Patient w/ ESRD (patient on haemodialysis) Initially 0.25 mg tds. Max: 18 mg daily. Restless legs syndrome Initially 0.25 mg once daily for 2 days, may be increased to 0.5 mg once daily for the remainder of wk 1. Dose titration: Wk 2: 1 mg once daily, wk 3: 1.5 mg once daily, wk 4: 2 mg once daily, wk 5: 2.5 mg once daily, wk 6: 3 mg once daily, wk 7: 4 mg once daily.
Severe CV disease, history or presence of major psychotic disorders. Paradoxical worsening of restless legs syndrome symptoms. Avoid abrupt discontinuation. Co-administration w/ antihypertensive & antiarrhythmic agents. May affect ability to drive & use machines. Not recommended in hepatic impairment. Severe renal impairment, ESRD. Not to be used during pregnancy & lactation. Not recommended in childn & adolescents <18 yr.
Sign Out
